Theradiag (Paris: ALTER), a French company specializing in diagnostic tests for autoimmune and infectious diseases, today announces the market launch of a CE marked antigen test for the detection of COVID-19.
September 16, 20201, a decree of September 15, 2020, amending the decree of July 10, 2020 specifying the general measures necessary to combat the COVID-19 epidemic in regions emerging from the state of health emergency and those where it has occurred. extended, was published in the French Official Journal. In accordance with this ordinance, antigen tests are now officially approved for the detection
COVID-19 in asymptomatic patients in France, a measure intended to alleviate the pressure on medical biology laboratories.
The antigen test: a new diagnostic tool to fight COVID-19
Like RT-PCR testing, antigen testing is done using a swab to collect a nasopharyngeal sample.
The swab is then analyzed directly at the test site, without requiring any specific equipment or personnel. Delivering a result in less than 15 minutes after collection, the test detects the presence of proteins or fragments of the SARS-CoV-2 virus, unlike RT-PCR tests which determine the presence of genetic material (DNA, genomes, etc. ) belonging to the virus.
The test was developed by CerTest Biotec, a long-time Spanish partner of Theradiag specializing in the direct detection of respiratory pathogens using rapid tests.
Theradiag: the French specialist in laboratory diagnostics
Founded in 1986, Theradiag specializes in the development of diagnostics capable of measuring the effectiveness of treatments, particularly in the field of biotherapy, for autoimmune diseases and cancer, a discipline known under the name of theranostics (therapy + diagnosis ), in which Theradiag is the world leader.
Going beyond simple diagnosis, theranostics is designed to allow clinicians to define an individual treatment for each patient by monitoring the effectiveness of the treatment and anticipating the potential side effects inherent in biotherapies. Theradiag seeks to promote personalized medicine by establishing an individual treatment adapted to the specific needs of each patient.
The market launch of the antigen test is part of the Theradiag campaign launched in April to help fight COVID-19, involving the development of serological tests to detect antibodies specific to COVID-19 in patients. The new test expands Theradiag’s range of tools to diagnose COVID-19.
Bernard de Castelnau, CEO of Theradiag told me: “The current resurgence of COVID-19 infections has increased the need for rapid and effective diagnostic tests. By launching this antigen test in France, Theradiag intends to consolidate and intensify its support for patients and health authorities in the fight against this pandemic.
Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.
Theradiag was the pioneer of the “theranostic” test (combining therapy and diagnosis), which measures the effectiveness of biotherapy in the treatment of chronic inflammatory diseases. Beyond the simple diagnosis, theranostics aims to help clinicians set up a “personalized treatment” for each patient. This method promotes individualization of treatment, evaluation of its effectiveness and prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE marked TRACKER® range, a comprehensive solution of invaluable medical value.
The company is based in Marne-la-Vallée, near Paris, is present in more than 70 countries and employs more than 60 people.
For more information about Theradiag, please visit our website: www.theradiag.com
1 Source: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042331277